NASDAQ:NTLA Intellia Therapeutics (NTLA) Stock Price, News & Analysis $9.77 -0.01 (-0.10%) Closing price 11/18/2026 04:00 PM EasternExtended Trading$9.95 +0.18 (+1.85%) As of 08:20 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Intellia Therapeutics Stock (NASDAQ:NTLA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Intellia Therapeutics alerts:Sign Up Key Stats Today's Range$9.66▼$10.4950-Day Range$9.70▼$13.3252-Week Range$7.95▼$18.48Volume7.23 million shsAverage Volume4.63 million shsMarket Capitalization$1.37 billionP/E RatioN/ADividend YieldN/APrice Target$21.44Consensus RatingHold Company Overview Intellia Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing genome-editing treatments for serious diseases. Founded in 2014 and headquartered in Cambridge, Massachusetts, the company uses CRISPR/Cas9 technology to make targeted changes to DNA. Its research includes in vivo therapies, which are designed to edit genes inside a patient’s body, and ex vivo approaches, which involve modifying cells outside the body before they are returned to the patient. Intellia’s investigational programs have included treatments for transthyretin amyloidosis and hereditary angioedema. The company has also collaborated with Regeneron Pharmaceuticals on developing and commercializing certain CRISPR-based therapies. Intellia’s work is primarily in research and clinical development; its investigational treatments are not established as approved products. The company conducts development activities through clinical studies and industry partnerships.AI Generated. May Contain Errors. Read More Intellia Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks52nd Percentile Overall ScoreNTLA MarketRank™: 2.60229916518 of 5 starsIntellia Therapeutics scored higher than 52% of companies evaluated by MarketBeat, and ranked 847th out of 1,704 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.2 / 5Analyst RatingHold Consensus RatingIntellia Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 strong buy rating, 9 buy ratings, 7 hold ratings, and 4 sell ratings.Upside PotentialIntellia Therapeutics has a consensus price target of $21.44, representing about 119.5% upside from its current price of $9.77.Amount of Analyst CoverageIntellia Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Intellia Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Intellia Therapeutics are expected to grow in the coming year, from ($3.28) to ($2.32) per share.Price to Book Value per Share RatioIntellia Therapeutics has a P/B Ratio of 2.24. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted32.75% of the float of Intellia Therapeutics has been sold short.Short Interest Ratio / Days to CoverIntellia Therapeutics has a short interest ratio ("days to cover") of 11.05, which indicates bearish sentiment.Change versus previous monthShort interest in Intellia Therapeutics has recently decreased by 0.17%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldIntellia Therapeutics does not currently pay a dividend.Dividend GrowthIntellia Therapeutics does not have a long track record of dividend growth. News and Social Media2.0 / 5News Sentiment0.16 News SentimentIntellia Therapeutics has a news sentiment score of 0.16. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.38 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Intellia Therapeutics this week, compared to 6 articles on an average week.Search InterestOnly 10 people have searched for NTLA on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days.MarketBeat Follows9 people have added Intellia Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership1.6 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Intellia Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $131,080.00 in company stock.Percentage Held by Insiders3.50% of the stock of Intellia Therapeutics is held by insiders.Percentage Held by Institutions88.77% of the stock of Intellia Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Intellia Therapeutics' insider trading history. Receive NTLA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Intellia Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NTLA Stock News HeadlinesIntellia Therapeutics (NTLA) Receives a Buy from Canaccord GenuityNovember 18 at 6:17 PM | theglobeandmail.comIntellia Therapeutics (NTLA), Why Is It Back In The Spotlight?November 17 at 9:49 AM | finance.yahoo.comMy $247 scanner for $7Bill Poulos is cutting the price of his $247 Instant Scanner to $7 for Black Friday. It's a one-time payment that covers a full year, with no subscription and no re-bills. Every night after the close, the scanner screens nearly a thousand of America's biggest stocks. It returns a short list of qualifying setups with the exact buy price next to each one. There's nothing to install. If you decide it's not for you, you get the $7 back and keep the scanner for the year.November 19 at 1:00 AM | Profits Run (Ad)Intellia Therapeutics, Inc. (NTLA) Discusses Lonvo-z Clinical Data and Commercial Launch Preparations in HAE TranscriptNovember 12, 2026 | seekingalpha.comIntellia Therapeutics Presents Additional Positive Clinical and Patient-Reported Data for Lonvoguran Ziclumeran (lonvo-z) at ACAAI 2026November 12, 2026 | globenewswire.comBrookline Capital Markets Predicts NTLA FY2026 EarningsNovember 12, 2026 | americanbankingnews.comResearch Analysts Offer Predictions for NTLA FY2026 EarningsNovember 12, 2026 | americanbankingnews.comIntellia Therapeutics (NASDAQ:NTLA) CEO John Leonard Sells 9,000 Shares of Company StockNovember 4, 2026 | insidertrades.comSee More Headlines NTLA Stock Analysis - Frequently Asked Questions How have NTLA shares performed this year? Intellia Therapeutics' stock was trading at $8.99 on January 1st, 2026. Since then, NTLA stock has increased by 8.7% and is now trading at $9.77. How were Intellia Therapeutics' earnings last quarter? Intellia Therapeutics, Inc. (NASDAQ:NTLA) released its earnings results on Thursday, November, 5th. The company reported ($0.91) earnings per share for the quarter, missing the consensus estimate of ($0.80) by $0.11. The company's revenue was down 47.8% on a year-over-year basis. When did Intellia Therapeutics IPO? Intellia Therapeutics (NTLA) raised $102 million in an initial public offering (IPO) on Friday, May 6th 2016. The company issued 6,000,000 shares at a price of $16.00-$18.00 per share. Credit Suisse, Jefferies and Leerink Partners served as the underwriters for the IPO and Wedbush PacGrow was co-manager. Who are Intellia Therapeutics' major shareholders? Intellia Therapeutics' top institutional investors include State Street Corp (5.56%), Sumitomo Mitsui Trust Group Inc. (2.57%), Goldman Sachs Group Inc. (1.54%) and Baker BROS. Advisors LP (0.59%). Insiders that own company stock include John M Leonard, Edward J Dulac III, William J Chase, James Basta, Birgit C Schultes, Eliana Clark, Michael P Dube, David Lebwohl, Laura Sepp-Lorenzino, Glenn Goddard and Jesse Goodman. View institutional ownership trends. How do I buy shares of Intellia Therapeutics? Shares of NTLA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Intellia Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Intellia Therapeutics investors own include CRISPR Therapeutics (CRSP), Editas Medicine (EDIT), NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), Micron Technology (MU) and Block (XYZ). Company Calendar Last Earnings11/05/2026Today11/19/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1w+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 For the last 7 days, NTLA's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:NTLA CIK1652130 Webwww.intelliatx.com Phone(857) 285-6200FaxN/AEmployees377Year Founded2014Price Target and Rating Average Price Target for Intellia Therapeutics$21.44 High Price Target$49.00 Low Price Target$8.00 Potential Upside/Downside+119.5%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage21 Analysts Profitability EPS (Trailing Twelve Months)($3.35) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$412.69 million Net Margins-805.75% Pretax Margin-805.75% Return on Equity-64.74% Return on Assets-50.72% Debt Debt-to-Equity RatioN/A Current Ratio6.31 Quick Ratio6.31 Sales & Book Value Annual Sales$67.67 million Price / Sales20.26 Cash FlowN/A Price / Cash FlowN/A Book Value$4.37 per share Price / Book2.24Miscellaneous Outstanding Shares140,360,000Free Float135,446,000Market Cap$1.37 billion OptionableOptionable Beta1.83 Social Links The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NASDAQ:NTLA) was last updated on 11/18/2026 by MarketBeat.com Staff. From Our PartnersChase, Wells Fargo and Capital One all showed errors on Nov. 16On November 16, customers of Chase, Bank of America, Wells Fargo, Capital One and Zelle reported errors when t...Cedar Gold Group | SponsoredYour $7 scanner is waitingThe Instant Scanner is $7 in Bill Poulos's Black Friday sale. Every night it delivers a list showing which sto...Profits Run | SponsoredPentagon magnet restrictions take effect January 1, 2027A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It...OilPrice | SponsoredThe Democrats can’t stop thisPorter Stansberry believes President Trump has begun a full dollar reset through executive order 14241, bypass...Porter & Company | SponsoredTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Tradi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredYour father's savings lost half their value after 1971.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredA Bill Would Reprice America's Gold at Market ValueThe US government still values its gold at $42 an ounce, a price Congress set in 1973. Gold trades above $4,00...Concord Gold Capital | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Intellia Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Intellia Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.